Noradrenergic dysregulation in the locus coeruleus: Implications for neuropsychiatric disease pathophysiology- A...

The locus coeruleus [LC] is a dense cluster of noradrenergic neurons located in the dorsal pons of the brainstem and serves as the brain's principal source of noradrenaline (NA). This neuromodulatory system plays a central role in regulating arousal, attention, stress response, sleep-wake cycles, and emotional behavior. The LC's extensive efferent projections render it highly sensitive to both external environmental stressors and intrinsic factors, including age-related neuronal loss, which can compromise cognitive function, emotional regulation, and psychiatric stability. Emerging evidence implicates dysfunction in LC-noradrenergic signaling as a shared pathophysiological mechanism underlying multiple neuropsychiatric disorders, including major depressive disorder, schizophrenia, autism spectrum disorder, obsessive-compulsive disorder, and post-traumatic stress disorder. This review integrates current clinical, neuroanatomical, and functional studies to highlight how aberrant LC-noradrenergic dynamics contribute to key features of these psychiatric disorders, such as impaired cognitive control, emotional dysregulation, altered sensory processing, and maladaptive stress responses. We also highlight the critical interplay between LC dysfunction and disrupted sleep-wake architecture owing to the importance of the LC in sleep-wake regulation. Disruptions in LC activity profoundly affect both rapid eye movement (REM) and non-REM sleep, which in turn exacerbate psychiatric symptoms, including insomnia, hypervigilance, and affective instability. By synthesizing findings from rodent models, human neuroimaging studies, and post-mortem analyses, we reveal distinct patterns of LC pathology in this narrative review, ranging from hypoactivity and dendritic atrophy to hyperresponsivity and excessive NA release that are associated with symptoms of psychiatric disorders. Finally, we review recent advances in neuromodulatory strategies targeting LC-noradrenergic pathways, including pharmacotherapies (e.g., α2-adrenergic agonists, NA reuptake inhibitors), chemogenetics, and non-invasive brain stimulation techniques. These emerging therapies offer promising avenues for restoring LC-mediated network homeostasis and improving clinical outcomes in treatment-resistant psychiatric populations. In summary, this review positions LC as a convergent hub of vulnerability and a compelling therapeutic target in neuropsychiatric disease. Elucidating the mechanisms of LC-NA dysfunction holds potential not only for refining disease models but also for advancing precision medicine approaches for complex psychiatric disorders.